Modality
Vaccine
MOA
CGRPant
Target
EZH2
Pathway
PI3K/AKT
CMLTTR AmyloidosisNSCLC
Development Pipeline
Preclinical
~Mar 2021
→ ~Jun 2022
Phase 1
Sep 2022
→ Sep 2028
Phase 1Current
NCT06682025
148 pts·NSCLC
2022-09→2025-01·Active
NCT04244914
1,392 pts·CML
2025-03→2028-09·Completed
1,540 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-01-101.2y agoPh2 Data· NSCLC
2028-09-032.4y awayPh2 Data· CML
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Active
P1/2
Complet…
Catalysts
Ph2 Data
2025-01-10 · 1.2y ago
NSCLC
Ph2 Data
2028-09-03 · 2.4y away
CML
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06682025 | Phase 1/2 | NSCLC | Active | 148 | BodyWt |
| NCT04244914 | Phase 1/2 | CML | Completed | 1392 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Rilufotisoran | Samsung Biologics | NDA/BLA | FXIa |